Avience Biomedicals Ltd.
•₹ 255.96.63%
2026-08-21
PROS
- Company comfortably covers its interest (7.5x coverage)
CONS
- Receivables are growing faster than sales - a possible quality concern
- Working capital days have increased from 34 to 110 days
- Total debt has risen sharply - up 46.4% year on year
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
EDIT COLUMNS| S.No. | Name | CMP Rs. | P/E | Mar Cap Rs.Cr. | Div Yld % | NP Qtr Rs.Cr. | Qtr Profit Var % | Sales Qtr Rs.Cr. | Qtr Sales Var % | ROCE % | OPM % |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | LENSKART | 639.30 | 169.67 | 111193.84 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| 2. | POLYMED | 1771.60 | 56.99 | 17957.20 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| 3. | MOLBIO | 1040.35 | 71.97 | 11988.99 | 0.00 | — | — | — | — | 19.79 | — |
| 4. | LAXMIDENTL | 195.65 | 34.85 | 1076.50 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| 5. | 3BBLACKBIO | 1145.55 | 17.71 | 983.19 | 0.44 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| 6. | AVIENCE | 234.90 | 14.72 | 128.84 | 0.00 | — | — | — | — | 34.16 | — |
| 7. | GKB | 63.95 | 9.94 | 32.23 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Detailed Comparison with:
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
No quarterly results found
We don't have this information yet. Please check back later.
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 24 | 45 | |
| 20 | 34 | |
| Operating Profit | 5 | 12 |
| OPM % | 19 | 27 |
| Other Income | 0 | 1 |
| Interest | 1 | 2 |
| Depreciation | 1 | 1 |
| 3 | 10 | |
| Tax % | 27 | 26 |
| Net Profit | 2 | 7 |
| EPS | 7 | 18 |
| Dividend Payout % | 0 | 0 |
| Minority Interest | 0 | 0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 7 | 18 |
| Minority Interest | 0 | 0 |
| Share of Associates | 0 | 0 |
| Adjusted EPS | 7 | 18 |
Mar 2024
- 24
- 20
- Operating Profit
- 5
- OPM %
- 19
- Other Income
- 0
- Interest
- 1
- Depreciation
- 1
- 3
- Tax %
- 27
- Net Profit
- 2
- EPS
- 7
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 7
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 7
Mar 2025
- 45
- 34
- Operating Profit
- 12
- OPM %
- 27
- Other Income
- 1
- Interest
- 2
- Depreciation
- 1
- 10
- Tax %
- 26
- Net Profit
- 7
- EPS
- 18
- Dividend Payout %
- 0
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 18
- Minority Interest
- 0
- Share of Associates
- 0
- Adjusted EPS
- 18
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- Last Year:
- 50%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| LIABILITIES | - | - |
| Equity Capital | 3 | 4 |
| 3 | 19 | |
| 7 | 11 | |
| Trade Payables | 6 | 7 |
| 16 | 15 | |
| Total Liabilities | 35 | 56 |
| ASSETS | - | - |
| 10 | 13 | |
| Capital Work in Progress | 0 | 5 |
| 12 | 13 | |
| 8 | 17 | |
| Cash & Bank | 0 | 5 |
| 3 | 3 | |
| Total Assets | 35 | 56 |
| Total Debt | 15 | 22 |
| Net Working Capital | 2 | 14 |
| Contingent Liabilities | 0 | 0 |
| Book Value per Share | 18.91 | 56.50 |
| Face Value | 10.00 | 10.00 |
| Total Debt | 15 | 22 |
| Net Working Capital | 2 | 14 |
| Contingent Liabilities | 0 | 0 |
| Book Value per Share | 18.91 | 56.50 |
| Face Value | 10.00 | 10.00 |
Mar 2024
- Equity Capital
- 3
- 3
- 7
- Trade Payables
- 6
- 16
- Total Liabilities
- 35
- 10
- Capital Work in Progress
- 0
- 12
- 8
- Cash & Bank
- 0
- 3
- Total Assets
- 35
- Total Debt
- 15
- Net Working Capital
- 2
- Contingent Liabilities
- 0
- Book Value per Share
- 18.91
- Face Value
- 10.00
- Total Debt
- 15
- Net Working Capital
- 2
- Contingent Liabilities
- 0
- Book Value per Share
- 18.91
- Face Value
- 10.00
Mar 2025
- Equity Capital
- 4
- 19
- 11
- Trade Payables
- 7
- 15
- Total Liabilities
- 56
- 13
- Capital Work in Progress
- 5
- 13
- 17
- Cash & Bank
- 5
- 3
- Total Assets
- 56
- Total Debt
- 22
- Net Working Capital
- 14
- Contingent Liabilities
- 0
- Book Value per Share
- 56.50
- Face Value
- 10.00
- Total Debt
- 22
- Net Working Capital
- 14
- Contingent Liabilities
- 0
- Book Value per Share
- 56.50
- Face Value
- 10.00
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1 | 4 | |
| Cash from Investing | -4 | -9 |
| Cash from Financing | 3 | 9 |
| -0 | 4 | |
| Free Cash Flow | 1 | -4 |
| OCF / Net Profit | 0.46 | 0.50 |
| Cumulative 5-Year FCF | 0 | 0 |
| OCF / Net Profit | 0.46 | 0.50 |
| Cumulative 5-Year FCF | 0 | 0 |
Mar 2024
- 1
- Cash from Investing
- -4
- Cash from Financing
- 3
- -0
- Free Cash Flow
- 1
- OCF / Net Profit
- 0.46
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.46
- Cumulative 5-Year FCF
- 0
Mar 2025
- 4
- Cash from Investing
- -9
- Cash from Financing
- 9
- 4
- Free Cash Flow
- -4
- OCF / Net Profit
- 0.50
- Cumulative 5-Year FCF
- 0
- OCF / Net Profit
- 0.50
- Cumulative 5-Year FCF
- 0
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| PER SHARE | - | - |
| EPS (₹) | 6.52 | 17.94 |
| Book Value (₹) | 18.91 | 56.50 |
| Dividend per Share (₹) | 0.00 | 0.00 |
| Cash EPS (₹) | 8.40 | 20.07 |
| PROFITABILITY | - | - |
| Operating Margin % | 17.13% | 25.31% |
| Net Margin % | 8.93% | 15.99% |
| ROE % | 34.47% | 49.90% |
| ROCE % | 18.25% | 34.16% |
| 6.20% | 15.90% | |
| EFFICIENCY | - | - |
| Debtor Days | 123 | 102 |
| Inventory Days | 189 | 103 |
| Payable Days | 130 | 86 |
| 182 | 118 | |
| FINANCIAL HEALTH | - | - |
| Debt to Equity (x) | 2.44x | 0.97x |
| Interest Coverage (x) | 4.10x | 7.45x |
| 1.11x | 1.58x | |
| GROWTH | - | - |
| Revenue Growth % | 0.00% | 88.77% |
| Operating Profit Growth % | 0.00% | 169.91% |
| Net Profit Growth % | 0.00% | 237.76% |
| 0.00% | 175.19% | |
| VALUATION | - | - |
| P/E (x) | 0.00x | 0.00x |
| P/B (x) | 0.00x | 0.00x |
| Dividend Yield % | 0.00% | 0.00% |
| 4.00x | 1.75x |
Mar 2024
- EPS (₹)
- 6.52
- Book Value (₹)
- 18.91
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 8.40
- Operating Margin %
- 17.13%
- Net Margin %
- 8.93%
- ROE %
- 34.47%
- ROCE %
- 18.25%
- 6.20%
- Debtor Days
- 123
- Inventory Days
- 189
- Payable Days
- 130
- 182
- Debt to Equity (x)
- 2.44x
- Interest Coverage (x)
- 4.10x
- 1.11x
- Revenue Growth %
- 0.00%
- Operating Profit Growth %
- 0.00%
- Net Profit Growth %
- 0.00%
- 0.00%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 4.00x
Mar 2025
- EPS (₹)
- 17.94
- Book Value (₹)
- 56.50
- Dividend per Share (₹)
- 0.00
- Cash EPS (₹)
- 20.07
- Operating Margin %
- 25.31%
- Net Margin %
- 15.99%
- ROE %
- 49.90%
- ROCE %
- 34.16%
- 15.90%
- Debtor Days
- 102
- Inventory Days
- 103
- Payable Days
- 86
- 118
- Debt to Equity (x)
- 0.97x
- Interest Coverage (x)
- 7.45x
- 1.58x
- Revenue Growth %
- 88.77%
- Operating Profit Growth %
- 169.91%
- Net Profit Growth %
- 237.76%
- 175.19%
- P/E (x)
- 0.00x
- P/B (x)
- 0.00x
- Dividend Yield %
- 0.00%
- 1.75x
Documents
Announcements
Nothing filed yet.
Annual Reports
Nothing filed yet.
Credit Ratings
Nothing filed yet.
Concalls
Nothing filed yet.